Pr FORNECKER Luc-Matthieu

Fiche personne

Coordonnées

Hôpital de Hautepierre
17 rue Albert Calmette
BP 23025
67033 STRASBOURG

03 88 12 76 70

Territoire

Alsace

Statut

Hospitalo-Universitaire

Affiliation

Hôpitaux universitaires de Strasbourg (HUS)

Recherche

Expertises :
- Clinique:Hématologie

Projets

Essai de phase 2, multicentrique, randomisé contre placebo, évaluant l’efficacité d’un traitement par hydroxychloroquine et azithromycine chez des patients atteints de COVID-19 et porteurs d’une hémopathie maligne

2020 - Porteur du projet : Pr FORNECKER Luc-Matthieu

Publications

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Sesques P, Manson G, Dubois S, Gros FX, Brisou G, Sarkozy C, Bernard S, Bourbon E, Fornecker LM, Durot E, Martin L, Chassagne-Clément C, Llamas Gutierrez F, Syrykh C, Delfau-Larue MH, Kanoun S, Vercellino L, Bodet-Milin C, Bahri H, Zhang Yin J, Dony A, Lebras L, Ochmann M, Baron M, Monjanel H, Le Calloch R, Claves F, Kirova Y, Gisselbrecht C, Guidez S, Bossard JB, Di Blasi R, Delette C, Fouillet L, Rhomdani M, Belhadj M, Crochet G, Amorim S, Safa F, Drieu La Rochelle L, Abraham J, Thieblemont C, Jardin F, Noel R, Bailly S, Renaud L, Guillermin Y, Delapierre B, Choquet S, Roulin L, Lamure S, Galicier L, Al Tabaa Y, Soussain C, Guièze R, Houot R, Tessoulin B

Eur J Cancer. 2025 12 3;232:116070

Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.

Mauvieux L, Herbrecht R, Eischen A, Galoisy AC, Rolland D, Gervais C, Mayeur-Rousse C, Hueber-Bonnot S, Nicolae A, Fornecker LM, Goetsch T, Severac F, Bizoï R, Fabacher T, Miguet L

Blood Adv. 2025 11 25;9(22):5880-5887

Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.

Letailleur V, Chaillol I, Cherblanc F, Ghesquières H, Peyrade F, Guidez S, Bijou F, Sesques P, Rossi C, Fornecker LM, Fouillet L, Carras S, Chartier L, Belot A, Oberic L, Jardin F, Tessoulin B

Blood Cancer J. 2025 11 3;15(1):190

Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness.

Couvidou A, Wald M, Angénieux C, Pires-Marafon J, Apithy MJ, Humbrecht C, Fornecker LM, Congy-Jolivet N, Dupuis A, Rollin J, Maître B

Haematologica. 2025 09 18;:

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study.

Brisou G, Paillassa J, Bernard S, Tournilhac O, Fornecker LM, Maloisel F, Gastaud L, Durot E, Tempescul A, Braun T, Ivanov V, Cherel B, Serrier C, Delage J, El Yamani A, Delapierre B, Lebras L, Lestang E, Villesuzanne C, Agape P, Escure G, Fouillet L, Nicol C, Olivier G, Levy A, Le Bris AS, Cassuto O, Jacquemelle L, Haioun C, Herbaux C

Haematologica. 2025 05 15;:

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Herbaux C, Bachy E, Bouabdallah R, Guidez S, Casasnovas O, Feugier P, Damaj G, Tilly H, Ysebaert L, Le Gouill S, Morineau N, Gyan E, Gressin R, Houot R, Cheminant M, Morschhauser F, Thieblemont C, Haioun C, Nicolas-Virelizier E, Fornecker LM, Daguindau N, Cartron G

Br J Haematol. 2025 04 26;:

Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and

Martínez C, Khvedelidze I, Fekom M, Deau Fischer B, Marouf A, Ghesquières H, Fornecker LM, Merli F, Stefani PM, Massaro F, Botto B, Ferhanoğlu B, Akay OM, Özbalak M, Espeso de Haro M, Romero S, Galimard JE, Glass B, Bazarbachi A, Sureda A

Bone Marrow Transplant. 2025 04 15;:

Interim PET after 4 Cycles Predicts Outcome in Histomolecularly Confirmed Primary Mediastinal B-Cell Lymphoma.

Camus V, Molina TJ, Desmots F, Blanc-Durand P, Kanoun S, Moslemi A, Ruminy P, Le Gouill S, Ghesquieres H, Obéric L, Morschhauser F, Tilly H, Ribrag V, Houot R, Thieblemont C, Maisonneuve HG, Claves F, Bouabdallah K, Haioun C, Damaj G, Fornecker LM, Noel R, Feugier P, Sibon D, Cartron G, Bonnet C, Bernard W, Kraeber-Bodere F, Bodet-Milin C, Jais JP, Briere J, Rossi C, Elsensohn MH, Chartier L, Itti E, Jardin F, Fest T

Blood Adv. 2025 03 3;:

Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.

Lamure S, Chavez HH, de Goër de Herve MG, Fornecker LM, Drenou B, Jacquet C, Merabet F, Kohn M, Quélin F, Jackson A, Choquet S, Duléry R, Taoufik Y, Besson C

Front Immunol. 2025 01 20;15:1524813

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.

Bommier C, Donzel M, Rossi C, Fornecker LM, Bijou F, Chauchet A, Lebras L, Ysabaert L, Haioun C, Bouabdallah K, Gastinne T, Morineau N, Amorim S, Jardin F, Abraham J, Lamy de la Chapelle T, Gressin R, Fouillet L, Fruchart C, Olivier G, Morschhauser F, Cherblanc F, Belot A, Le Guyader S, Monnereau A, Ghesquieres H, Thieblemont C

Hematol Oncol. 2024 11;42(6):e3314

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.

Rossi C, Manson G, Marouf A, Cabannes-Lamy A, Nicolas-Virelizier E, Maerevoet M, Alcantara M, Molina L, Ceraulo A, Poirée M, Galtier J, Diop N, Delette C, Segot A, Dubois S, Waultier A, Bernard S, Noël R, Guidez S, Kohn M, Bailly S, Moatti H, Touati M, Renaud L, Kanoun S, Cottereau AS, Kirova Y, Peignaux K, Dourthe ME, Simonin M, Leblanc T, Quéro L, Krzisch D, Duléry R, Grenier A, Gastinne T, Casasnovas O, Gallamini A, André M, Morschhauser F, Deau B, Fornecker LM, Ghesquières H

Eur J Cancer. 2024 10 22;213:115073

[Nurturing and growing a community of department heads: Act 2 in haematology].

Houot R, Calmettes C, Park S, Pascal L, Peffault de Latour R, Pigneux A, Quinquenel A, Raffoux E, Thieblemont C, Touati M, Trebouet A, Vaida I, Wémeau M, Bastie JN, Bay JO, Cluzeau T, Cornillon J, Damaj G, Deconinck E, Feugier P, Fornecker LM, Gay J, Hermine O, Hospital MA, Hunault M, Jaccard A, Jardin F, Le Calloch R, Legros L, Leleu X, Lemonnier F, Malfuson JV, Morel P, Ochmann M, Orsini-Piocelle F, Gyan E

Bull Cancer. 2024 09 11;:

[Acute myeloid leukemia with mutated RUNX1 at the university hospitals of Strasbourg].

Panaget B, Mauvieux L, Miguet L, Fornecker LM, Lioure B, Ledoux MP, Rolland D, Mayeur-Rousse C

Ann Biol Clin (Paris). 2024 08 30;82(3):266-280

Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.

Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Obéric L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj G, Guidez S, Carras S, Fornecker LM, Choquet S, Hermine O, Paillassa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F

Blood Adv. 2024 08 20;:

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.

Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P

Nat Commun. 2024 08 9;15(1):6822

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.

Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker LM, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detourmignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H

Eur J Cancer. 2024 07 4;208:114210

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F

Lancet Haematol. 2024 06;11(6):e406-e414

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.

Alig SK, Esfahani MS, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA

Nature. 2023 12 11;:

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.

Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burroni B, Callanan M, Le Gouill S, Gressin R

Haematologica. 2023 11 30;:

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.

Ghesquieres H, Cherblanc F, Belot A, Micon S, Bouabdallah K, Esnault C, Fornecker LM, Thokagevistk K, Bonjour M, Bijou F, Haioun C, Morineau N, Ysebaert L, Damaj G, Tessoulin B, Guidez S, Morschhauser F, Thieblemont C, Chauchet A, Gressin R, Jardin F, Fruchart C, Labouré G, Fouillet L, Lionne-Huyghe P, Bonnet A, Lebras L, Amorim S, Leyronnas C, Olivier G, Guieze R, Houot R, Launay V, Drénou B, Fitoussi O, Detourmignies L, Abraham J, Soussain C, Lachenal F, Pica GM, Fogarty P, Cony-Makhoul P, Bernier A, Le Guyader-Peyrou S, Monnereau A, Boissard F, Rossi C, Camus V

Blood Adv. 2023 10 24;:

[Creating a community of heads of department to meet hospital system challenges: First experience in haematology].

Houot R, Bay JO, Chevallier P, Choquet S, Fornecker LM, Ianotto JC, Jaccard A, Jardin F, Legros L, Lemonnier F, Park S, Pascal L, Soussain C, Gyan E

Bull Cancer. 2023 07 26;:

SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study.

Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M

Hemasphere. 2023 06;7(6):e887

Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, Debureaux PE, Cavalieri D, Fornecker LM, Casasnovas RO, Herbaux C, Amorim S, Rossi C, Bouscary D, Brice P, Ghesquieres H, Tamburini J, Deau B

Br J Haematol. 2023 05 16;:

Bruton's tyrosine kinase (BTK) gene overexpression is associated with risk of lymphoma in primary Sjögren's syndrome.

Duret PM, Schleiss C, Kawka L, Meyer N, Ye T, Saraux A, Devauchelle-Pensec V, Seror R, Larroche C, Perdriger A, Sibilia J, Vallat L, Fornecker LM, Nocturne G, Mariette X, Gottenberg JE

Arthritis Rheumatol. 2023 04 28;:

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O, Morineau N, Herbaux C, Gastinne T, Fornecker LM, Haioun C, Launay V, Araujo C, Benbrahim O, Sanhes L, Gressin R, Gonzalez H, Morschhauser F, Ternant D, Xerri L, Tarte K, Pranger D

J Clin Oncol. 2023 04 18;:JCO2202327

A fixed-duration, immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Michallet AS, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy MS, Morisset S, Rouille V, Mahe B, Laribi K, Villemagne B, Ferrant EF, Tournilhac O, Delmer AJ, Molina L, Leblond V, Tomowiak C, De Guibert S, Orsini Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Aurran Schleinitz T, Cymbalista F, Leprêtre S, Lévy V, Nguyen-Khac F, Feugier P

Blood Adv. 2023 04 7;:

Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.

Chaubard S, Marouf A, Lavergne D, Lemonnier F, Rossignol J, Clavert A, Gressin R, Cartron G, Waultier-Rascalou A, Vargaftig J, Salles G, Bachy E, Ghesquières H, Tournilhac O, Chauchet A, Le Gouill S, Damaj G, Fornecker LM, Sibon D, Obéric L, Michot JM, Gaulard P, Hermine O, Couronné L, Jaccard A

Br J Haematol. 2023 02 17;:

Retrospective analysis of a cohort of 41 B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).

Algrin C, Pérol L, Chapiro E, Baseggio L, Maloum K, Settegrana C, Lesesve JF, Siavellis J, Delmer A, Michallet AS, Ferrant E, Feugier P, Tomowiak C, Brion A, Ghez D, Fornecker LM, Ivanoff S, Struski S, Sutton L, Radford-Weiss I, Eclache V, Lefebvre C, Leblond V, Nguyen-Khac F, Roos-Weil D

Haematologica. 2022 12 22;:

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M,

J Clin Oncol. 2022 07 22;:JCO2101281

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.

Claustre G, Boulanger C, Maloisel F, Etienne-Selloum N, Fornecker LM, Durot E, Slimano F, Graff V

J Cancer Res Clin Oncol. 2022 07 5;:

Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.

Le Borgne P, Feuillassier L, Schenck M, Herbrecht JE, Janssen-Langenstein R, Simand C, Gantzer J, Nannini S, Fornecker LM, Alamé K, Lefebvre F, Castelain V, Schneider F, Clere-Jehl R

Cancers (Basel). 2022 06 29;14(13):

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.

Rossi C, André M, Dupuis J, Morschhauser F, Joly B, Lazarovici J, Ghesquières H, Stamatoullas A, Nicolas-Virelizier E, Feugier P, Gac AC, Moatti H, Fornecker LM, Deau B, Joubert C, Fortpied C, Raemaekers J, Federico M, Kanoun S, Meignan M, Traverse-Glehen A, Cottereau AS, Casasnovas RO

Haematologica. 2022 05 31;:

Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.

Bonnet A, Bossard C, Gabellier L, Rohmer J, Laghmari O, Parrens M, Sarkozy C, Dulery R, Roland V, Llamas-Gutierrez F, Oberic L, Fornecker LM, Bounaix L, Villemagne B, Szablewski V, Choquet S, Bouabdallah K, Traverse-Glehen A, Mohty M, Sanhes L, Houot R, Gastinne T, Leux C, Le Gouill S

Cancer Med. 2022 May 10;:

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.

Schenone L, Houillier C, Tanguy ML, Choquet S, Agbetiafa K, Ghesquières H, Damaj G, Schmitt A, Bouabdallah K, Ahle G, Gressin R, Cornillon J, Houot R, Marolleau JP, Fornecker LM, Chinot O, Peyrade F, Bouabdallah R, Moluçon-Chabrot C, Gyan E, Chauchet A, Casasnovas O, Oberic L, Delwail V, Abraham J, Roland V, Waultier-Rascalou A, Willems L, Morschhauser F, Fabbro M, Ursu R, Thieblemont C, Jardin F, Tempescul A, Malaise D, Touitou V, Nichelli L, Le Garff-Tavernier M, Plessier A, Bourget P, Bonmati C, Wantz-Mézières S, Giordan Q, Dorvaux V, Charron C, Jabeur W, Hoang-Xuan K, Taillandier L, Soussain C,

Bone Marrow Transplant. 2022 Apr 14;:

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.

Costes-Tertrais D, Hueso T, Gastinne T, Thieblemont C, Oberic L, Bouabdallah K, Garciaz S, Tchernonog E, Dartigeas C, Ribrag V, Fogarty P, Casasnovas RO, Houot R, Delette C, Malak S, Fornecker LM, Gressin R, Damaj G, Le Gouill S

Bone Marrow Transplant. 2022 Feb 11;:

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study.

Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P, Sibon D, Antoine C, Gastinne T, Borel C, Hammoud M, Sicard G, Gille R, Cavalieri D, Stamatoullas A, Filliatre-Clement L, Lazarovici J, Chauchet A, Fornecker LM, Amorin S, Rocquet M, Raus N, Burroni B, Rubio MT, Bouscary D, Quittet P, Casasnovas RO, Brice P, Ghesquieres H, Tamburini J, Deau B

Haematologica. 2021 Dec 30;:

[Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)].

Mathelin C, Barranger E, Boisserie-Lacroix M, Boutet G, Brousse S, Chabbert-Buffet N, Coutant C, Daraï E, Delpech Y, Duraes M, Espié M, Fornecker L, Golfier F, Grosclaude P, Hamy AS, Kermarrec E, Lavoué V, Lodi M, Luporsi É, Maugard CM, Molière S, Seror JY, Taris N, Uzan C, Vaysse C, Fritel X

Gynecol Obstet Fertil Senol. 2021 Dec 14;:

Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.

Vercueil C, Eberst L, Humbrecht C, Fornecker LM

Hemasphere. 2021 Dec;5(12):e655

Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.

Houillier C, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A, Fornecker LM, Hoang-Xuan K, Soussain C

Neurology. 2021 Sep 28;97(13):628-631

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years.

Jullien M, Tessoulin B, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Villemagne B, Gressin R, Bouabdallah K, Haioun C, Damaj G, Fornecker LM, Schiano De Colella JM, Feugier P, Hermine O, Cartron G, Bonnet C, André M, Bailly C, Casasnovas RO, Le Gouill S

Cancers (Basel). 2021 Sep 7;13(18):

Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).

Demeestere I, Racape J, Dechene J, Dupuis J, Morschhauser F, De Wilde V, Lazarovici J, Ghesquieres H, Touati M, Sibon D, Alexis M, Gac AC, Moatti H, Virelizier E, Maisonneuve H, Pranger D, Houot R, Fornecker LM, Tempescul A, André M, Casasnovas RO

J Clin Oncol. 2021 Jun 22;:JCO2100068

Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.

Lam M, Touitou V, Choquet S, Cassoux N, Ghesquières H, Kodjikian L, Schmitt A, Gattoussi S, Tabouret É, Sampo M, Blonski M, Angioi-Duprez K, Houot R, Mouriaux F, Gyan E, Le Lez ML, Moles MP, Croisé F, Chauchet A, Schwartz C, Ahle G, Meyer L, Gressin R, Chiquet C, Oberic L, Ollé P, Marolleau JP, Jany B, Tempescul A, Cochener B, Damaj G, Quintyn JC, Chabrot C, Rousseau E, Franciane P, Schneider C, Massé H, Bonnefoy JT, Brézin A, Fornecker LM, Ballonzoli L, Le Garff-Tavernier M, Hoang-Xuan K, Bodaghi B, Soussain C, Houillier C

Am J Hematol. 2021 Apr 17;:

The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA.

Buedts L, Wlodarska I, Finalet-Ferreiro J, Gheysens O, Dehaspe L, Tousseyn T, Fornecker LM, Lazarovici J, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Copie-Bergman C, Fabiani B, Dierickx D, Marcelis L, Vermeesch J, André M, Vandenberghe P

Blood Adv. 2021 Apr 13;5(7):1991-2002

Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia.

Schleiss C, Carapito R, Fornecker LM, Muller L, Paul N, Tahar O, Pichot A, Tavian M, Nicolae A, Miguet L, Mauvieux L, Herbrecht R, Cianferani S, Freund JN, Carapito C, Maumy-Bertrand M, Bahram S, Bertrand F, Vallat L

Leukemia. 2021 Apr 8;:

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort

Ghesquières H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Labouré G, Fitoussi O, Lebras L, Gressin R, Salles G, Ysebaert L, Monnereau A

BMC Public Health. 2021 Mar 2;21(1):432

Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA.

Le Gouill S, Ghesquieres H, Obéric L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve HG, Gressin R, Bouabdallah K, Haioun C, Damaj G, Fornecker LM, Bouabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger A, Briere J, Jais JP, Molina T, Itti E, Casasnovas O

Blood. 2020 Nov 19;:

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

Michallet AS, Letestu R, Le Garff-Tavernier M, Aanei CM, Ticchioni M, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles GA, Tournilhac O, Delmer AJ, Portois C, Pegourie B, Leblond V, Tomowiak C, De Guibert S, Orsini Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Feugier P

Blood. 2020 Nov 9;:

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO).

Quinquenel A, Aurran-Schleinitz T, Clavert A, Cymbalista F, Dartigeas C, Davi F, de Guibert S, Delmer A, Dilhuydy MS, Feugier P, Fornecker LM, Ghez D, Guieze R, Laribi K, Leblond V, Leprêtre S, Letestu R, Lévy V, Nguyen-Khac F, Michallet AS, Tomowiak C, Tournilhac O, Ysebaert L, Troussard X

Hemasphere. 2020 Oct;4(5):e473

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

Largeaud L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, Prade N, Dufrechou S, Plenecassagnes J, Luquet I, Blanchet O, Banos A, Béné MC, Bernard M, Bertoli S, Bonmati C, Fornecker LM, Guièze R, Haddaoui L, Hunault M, Ianotto JC, Jourdan E, Ojeda M, Peterlin P, Vey N, Zerazhi H, Yosr H, Mineur A, Cahn JY, Ifrah N, Récher C, Pigneux A, Delabesse E,

Leukemia. 2020 Sep 18;:

Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin.

Debureaux PE, Febvre de Nailly DL, Tavernier E, Bedoui M, Kuhnowski F, Tamburini J, Fornecker LM, Camus V, Sibon D, Moles MP, Glaisner S, Richardet JP, Mule S, Calderaro J, Azoulay D, Fadlallah J, Haioun C, Dupuis J

Bone Marrow Transplant.. 2020 Jan 20;:

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.

Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas RO, Durot E, Houot R, Tessoulin B, Tournilhac O, Malak S, Gyan E, Fornecker LM, Abraham J, Delapierre B, Peyrade F, Lemal R, Gressin R, Chantepie S, Borel C, Morello R, Bouabdallah K, Ibrahim A, Bouabdallah R, Le Gouill S, Damaj G

Bone Marrow Transplant.. 2020 Jan 17;:

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E

Neurology. 2020 Jan 6;:

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.

Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, Luquet I, De Mas V, Filleron T, Cassou M, Sarry A, Fornecker LM, Simand C, Bertoli S, Recher C, Delabesse E

. 2020 ;15(10):e0238795

Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.

Augé H, Notarantonio AB, Morizot R, Quinquenel A, Fornecker LM, Hergalant S, Feugier P, Broséus J

Front Immunol. 2020 ;11:594841

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P

Lancet Haematol. 2019 Jul 16;:

Prevalence of and mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study.

Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R, Feugier P, Roos-Weil D, Willems L, Michallet AS, Delmer A, Hormigos K, Levy V, Cymbalista F, Baran-Marszak F

Blood. 2019 Jun 26;:

High-Dose Therapy with Autologous Stem Cells Transplantation in Bing-Neel Syndrome: a retrospective analysis of 14 cases.

Simon L, Lemal R, Fornecker LM, Tournilhac O, Leblond V

Am. J. Hematol.. 2019 May 31;:

Evaluation of the effects of chemotherapy on brain glucose metabolism in children with Hodgkin's lymphoma.

Tauty A, Noblet V, Paillard C, Fornecker LM, Namer IJ, Bund C

Ann Nucl Med. 2019 May 13;:

Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.

Fornecker LM, Muller L, Bertrand F, Paul N, Pichot A, Herbrecht R, Chenard MP, Mauvieux L, Vallat L, Bahram S, Cianférani S, Carapito R, Carapito C

Sci Rep. 2019 Jan 29;9(1):895

BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo.

Schleiss C, Ilias W, Tahar O, Güler Y, Miguet L, Mayeur-Rousse C, Mauvieux L, Fornecker LM, Toussaint E, Herbrecht R, Bertrand F, Maumy-Bertrand M, Martin T, Fournel S, Georgel P, Bahram S, Vallat L

Sci Rep. 2019 Jan 24;9(1):701

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M

Lancet Oncol.. 2019 Jan 15;:

Tuberculosis and atypical mycobacterial infections in ruxolitinib treated patients with primary or secondary myelofibrosis or polycythemia vera.

Lescuyer S, Ledoux MP, Gravier S, Natarajan-Amé S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R

Int. J. Infect. Dis.. 2019 Jan 10;:

Tube-Gel: A Fast and Effective Sample Preparation Method for High-Throughput Quantitative Proteomics.

Muller L, Fornecker L, Cianferani S, Carapito C

Methods Mol. Biol.. 2019 ;1959:123-127

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia.

Contejean A, Resche-Rigon M, Tamburini J, Alcantara M, Jardin F, Lengliné E, Adès L, Bouscary D, Marçais A, Lebon D, Chabrot C, Terriou L, Barraco F, Banos A, Bussot L, Cahn JY, Hirsch P, Maillard N, Simon L, Fornecker LM, Socié G, Peffault de Latour R, Sicre de Fontbrune F

Haematologica. 2018 Sep 27;:

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C,

J. Clin. Oncol.. 2018 Sep 27;:JCO2018787366

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorveaux V, Bouabdallah K, Amorin S, Garidi R, Voillat L, Joly B, Solal Celigny P, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB

Haematologica. 2018 Aug 31;:

Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey.

Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, Fornecker L, Moreau S, Récher C, Nebout A

Haematologica. 2018 Jul 13;:

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Mauvieux L, Miguet L, Fornecker L

N. Engl. J. Med.. 2018 Jun 21;378(25):2442-3

Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?

Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck O, Vermersch P, Pruvo JP, Gerardin E, Lebrun-Frenay C, Lafitte F, Cottier JP, Clerc C, de Seze J, Dietemann JL, Kremer S

Eur Radiol. 2018 Jun 19;:

Extended investigation of tube-gel sample preparation: a versatile and simple choice for high throughput quantitative proteomics.

Muller L, Fornecker L, Chion M, Van Dorsselaer A, Cianférani S, Rabilloud T, Carapito C

Sci Rep. 2018 May 29;8(1):8260

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.

Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, Marolleau JP, Oberic L, Le Du K, Fornecker LM, Tournilhac O, Veillard AS, Chaillol I, Robin M, Tamburini J, Brice P

Br. J. Haematol.. 2018 May;181(3):341-349

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Poiré X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, Nguyen S, Forcade E, Régny C, Bay JO, Bazarbachi A, Rohrlich PS, Huynh A, Farhi J, Marchand T, Malfuson JV, Pilorge S, Labussière-Wallet H, Renard C, Fornecker LM, Detrait M, Duléry R, Delage J, Ménard AL, Charbonnier A, Nelken B, Jubert C, Suarez F, de la Tour RP, Beguin Y, Schoemans H, Blaise D, Yakoub-Agha I

Bone Marrow Transplant.. 2018 Apr;53(4):400-409

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.

Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E

Ann. Oncol.. 2018 Mar 1;29(3):715-723

Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review.

Paix A, Antoni D, Waissi W, Ledoux MP, Bilger K, Fornecker L, Noel G

Crit. Rev. Oncol. Hematol.. 2018 Mar;123:138-148

Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.

Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G

Am. J. Hematol.. 2018 Feb 23;:

Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening.

Martin M, Fornecker LM, Marcellin L, Mousseaux E, Hij A, Snowden JA, Farge D, Martin T

Bone Marrow Transplant.. 2017 Sep;:

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O,

N. Engl. J. Med.. 2017 09;377(13):1250-1260

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G,

JAMA. 2017 Aug;318(6):557-566

Triradial and quadriradial chromosomes detected in a case of B-cell prolymphocytic leukaemia.

Ittel A, Gervais C, Galoisy AC, M'Kacher R, Mauvieux L, Fornecker LM

Br. J. Haematol.. 2017 Aug;:

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.

Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A

Blood Cancer J. 2017 06 2;7(6):e568

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F

Blood. 2017 05 4;129(18):2471-2478

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L

Am. J. Hematol.. 2017 Mar;:

Hodgkin lymphoma of the maxillary sinus: A diagnostic trap?

Korenbaum C, Fornecker L, Noël G, Vigneron C

Eur Ann Otorhinolaryngol Head Neck Dis. 2017 Feb;134(1):47-48

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP

Haematologica. 2017 01;102(1):43-51

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G,

Oncotarget. 2016 Dec 20;7(51):85573-85583

Benchmarking sample preparation/digestion protocols reveals tube-gel being a fast and repeatable method for quantitative proteomics.

Muller L, Fornecker L, Van Dorsselaer A, Cianférani S, Carapito C

Proteomics. 2016 Dec;16(23):2953-2961

Adrenal lymphoma: presentation, management and prognosis.

Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM

QJM. 2016 Oct;:

Bendamustine conditioning for refractory type I cryoglobulinemia.

Martin M, Lipsker D, Fornecker LM, Toussaint E, Martin T

Joint Bone Spine. 2016 Oct;83(5):591-2

Spleen Uptake on Bone Scan After Frequent Platelet and RBC Transfusions.

De Marini P, Laplace A, Matuszak J, Fornecker LM, Namer IJ

Clin Nucl Med. 2016 Oct;41(10):802-3

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G

Lancet. 2016 Jun 11;387(10036):2402-11

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP

J. Clin. Oncol.. 2016 Jun;34(18):2125-32

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.

Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R

Am. J. Hematol.. 2016 Jun;91(4):366-70

Morel G, Oddou I, Fornecker LM

Rev Prat. 2016 May;66(5):e216

Morel G, Oddou I, Fornecker LM

Rev Prat. 2016 May;66(5):e217-e223

Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.

Gac AC, Azar N, Daguindau E, Cartron G, Fornecker LM, Gyan E, Broussais-Guillaumot F, Garidi R, Choufi B, Chantepie SP, Béné MC, Guiéze R, Bijou F, Gressin R, Amorim S, Damaj G

Leuk. Lymphoma. 2016 May;57(5):1149-53

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Blaise D, Poiré X, Nicolas-Virelizier E, Or R, Malladi R, Corby A, Fornecker L, Caballero D, Pohlreich D, Nagler A, Thieblemont C, Finke J, Bachy E, Vincent L, Schroyens W, Schouten H, Dreger P

Bone Marrow Transplant.. 2016 Mar;51(3):365-71

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S

Bone Marrow Transplant.. 2016 Mar;51(3):358-64